BR112012030814A2 - inibidores de jnk - Google Patents

inibidores de jnk

Info

Publication number
BR112012030814A2
BR112012030814A2 BR112012030814A BR112012030814A BR112012030814A2 BR 112012030814 A2 BR112012030814 A2 BR 112012030814A2 BR 112012030814 A BR112012030814 A BR 112012030814A BR 112012030814 A BR112012030814 A BR 112012030814A BR 112012030814 A2 BR112012030814 A2 BR 112012030814A2
Authority
BR
Brazil
Prior art keywords
jnk inhibitors
jnk
compounds
inhibitors
jnk activity
Prior art date
Application number
BR112012030814A
Other languages
English (en)
Inventor
Gong Leyi
Tan Yun-Chou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012030814A2 publication Critical patent/BR112012030814A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

inibidores de jnk. os compostos da fórmula (i) ou sais farmaceuticamente aceitáveis dos mesmos: onde m, n, p, q, x, y, z, a, r^ 1^, r^ 2^, r^ 3^, r^ 4^, r^ 5^ e r^ 6^ são conforme definidos no presente documento. os compostos e composições revelados no presente documento são úteis para modular a atividade de jnk e tratar as doenças associadas à atividade de jnk.
BR112012030814A 2010-06-04 2011-06-01 inibidores de jnk BR112012030814A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35159910P 2010-06-04 2010-06-04
PCT/EP2011/059003 WO2011151357A1 (en) 2010-06-04 2011-06-01 Inhibitors of jnk

Publications (1)

Publication Number Publication Date
BR112012030814A2 true BR112012030814A2 (pt) 2019-09-24

Family

ID=44510053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030814A BR112012030814A2 (pt) 2010-06-04 2011-06-01 inibidores de jnk

Country Status (10)

Country Link
US (1) US20110301170A1 (pt)
EP (1) EP2576559B1 (pt)
JP (1) JP2013527214A (pt)
KR (1) KR20130091308A (pt)
CN (1) CN102918046A (pt)
BR (1) BR112012030814A2 (pt)
CA (1) CA2799817A1 (pt)
MX (1) MX2012013438A (pt)
RU (1) RU2012155144A (pt)
WO (1) WO2011151357A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160023669A (ko) * 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
CN103864799B (zh) * 2014-03-17 2016-05-11 上海毕得医药科技有限公司 一种5,6,7,8-四氢咪唑[1,2-a]吡嗪的合成方法
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
CN110418789B (zh) * 2017-02-01 2022-03-25 常州千红生化制药股份有限公司 作为治疗剂的N-环烷基/杂环烷基-4-(咪唑并[1,2-a]吡啶)嘧啶-2-胺的衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
CA2662998C (en) * 2006-09-08 2015-10-06 F. Hoffmann-La Roche Ag Benzotriazole kinase modulators
AU2007328981B2 (en) * 2006-12-08 2013-07-11 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as JNK modulators
KR101368079B1 (ko) * 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
CN102471319B (zh) * 2009-08-10 2014-06-18 霍夫曼-拉罗奇有限公司 Jnk的抑制剂

Also Published As

Publication number Publication date
RU2012155144A (ru) 2014-07-20
WO2011151357A1 (en) 2011-12-08
EP2576559A1 (en) 2013-04-10
US20110301170A1 (en) 2011-12-08
JP2013527214A (ja) 2013-06-27
CN102918046A (zh) 2013-02-06
CA2799817A1 (en) 2011-12-08
MX2012013438A (es) 2013-01-22
KR20130091308A (ko) 2013-08-16
EP2576559B1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
BR112014008495A2 (pt) inibidores de proteína quinase
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EA201490949A1 (ru) Ингибиторы киназ
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
EA201201648A1 (ru) Стимуляторы sgc
BR112015001608A2 (pt) inibidor lfa-1 e polimorfo do mesmo
BR112013010018A2 (pt) inibidores de cdk
BRPI0908637B8 (pt) composto e composição farmacêutica do mesmo
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BRPI0519452A2 (pt) inibidores de cxcr2
MY172924A (en) Neprilysin inhibitors
BR112012019672A2 (pt) pirrolidina-2-carboxamidas substituídas.
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UA108240C2 (uk) Похідні гексафторізопропілкарбамату, їх одержання і їх терапевтичне застосування
BR112012017402A2 (pt) inibidores de vírus de flaviviridae

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.